PT - JOURNAL ARTICLE AU - Alexander Gamisch AU - Maria Elisabeth Mustafa TI - BA.4/BA.5 early surge report Austria AID - 10.1101/2022.07.12.22277534 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.12.22277534 4099 - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277534.short 4100 - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277534.full AB - More than two years into the COVID-19 pandemic, the emergence of the Omicron subvariants BA.4 and BA.5 initiated the fifth wave. BA.4/BA.5 share identical spike proteins and are thus difficult to differentiate using standard diagnostic tests. The true frequency and diversity of the two variants in Austria is therefore largely unknown. Aim of this report is to take stock about the frequency and diversity of BA.4 & BA.5 and their subvariants based on whole genome sequencing (WGS) data as deposited at GISAID database. Results show that most sequenced cases belong to BA.5 (c. 86 %) rather than BA.4 (c. 14 %) and that most of the global diversity (24 out of 32 subvariants) of BA.4 and BA.5 in terms of subvariants described is already present in Austria. However, most cases can be attributed to a few subvariants (e.g. BA.5.1, BE.1.1, BA.5.3, BA.5.2.1) with high estimated growth advantage over BA.2 (ranging 103 to 159 %) and may be worth monitoring as the immediate wave unfolds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors